Abbott Laboratories (NYSE: ABT) reported Q4 EPS of $1.51, $0.01 better than the analyst estimate of $1.50. Revenue for the quarter came in at $10.8 billion versus the consensus estimate of $10.58 billion.

Abbott Laboratories sees FY2013 ongoing EPS of $1.98-2.04, which the company called "strong."

For earnings history and earnings-related data on Abbott Laboratories (ABT) click here.

Earnings Guidance